Paul Nkansah, Ph.D. serves as Senior Director of Corporate Partnerships, responsible for the cultivation and management of industry research partnerships that support the advancement and commercialization of Johns Hopkins research. This team has been involved in life science deals with AbbVie, Bayer, Celgene and AstraZeneca, imaging agreements with Canon Medical and Toshiba, as well as collaborations around biomedical engineering, speech and language and health care delivery. The team manages relationships with approximately two-dozen industry partners.

Paul spent 14 years at Pfizer, first as a scientist in early-late formulation development and ultimately as a group lead/principal investigator, leading drug discovery teams and providing oversight to small molecule and biologic programs across a range of therapeutic areas. In his time at Pfizer, he participated in technology transfer/out-licensing, a corporate acquisition, and the formation of cooperative research agreements with academic institutions such as Harvard and Duke and with corporate peers such as AstraZeneca, Lilly and Sanofi.

Paul joined JHTV in 2021 from Global Health Consulting, where he served as chief scientific advisor. His team consulted for organizations on pharmaceutical development and supported life sciences clients in conducting and managing technology transfers, as well as providing guidance and oversight to global health supply chain projects totaling $620 million across 40 countries. Paul was also the Technical Director at United States Pharmacopeia from 2015-2019, where he helped lead a $110 million USAID-funded medicines quality assurance program.

Paul holds a Ph.D. in chemical engineering and master’s degrees in chemical engineering and pharmaceutics from the University of Michigan, where he subsequently taught as an adjunct faculty. He has been a Merck research fellow, authored numerous peer-reviewed publications and is a co-inventor of two patents on drug-delivery systems.